Senolytic therapy for age-related neurodegeneration

PARTIALLY ADDRESSED

Senolytics targeting p16/p21+ senescent astrocytes and microglia may reduce SASP-driven neuroinflammation.

Priority: 0.86 Domain: neurodegeneration Hypotheses: 1

📊 Landscape Analysis

Landscape Summary: Senolytic therapy for age-related neurodegeneration is a 0.86 priority gap in neurodegeneration. It has 1 linked hypotheses with average composite score 0.791. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Senolytic therapy for age-related neurodegeneration — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.791

Top Score

0.791

Avg Score

Debates

0.00

Avg Quality

60%

Resolution

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

Senescent Microglia Resolution via Maresins-Senolytics Combination

Target: BCL2L1 Pathway: Microglial activation / TREM2

0.791

score

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed

📈 Senescent Microglia Resolution via Maresins-Senolytics Combi score=0.791 2026-04-02T01:34

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps